|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR1900023342 |
|
最近更新日期: Date of Last Refreshed on: |
2020-11-09 13:18:33 |
|
注册时间: Date of Registration: |
2019-05-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
在中国真实世界环境中评估索磷布韦治疗方案用于慢性丙型肝炎病毒(HCV) 感染患者的安全性和有效性的批准上市后研究 |
|
Public title: |
A phase IV Study to Evaluate the Safety and Effectiveness of Sofosbuvir-containing Treatment Regimens in Patients with Chronic Hepatitis C Virus (HCV) Infection in a Chinese Real-World Setting |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
在中国真实世界环境中评估索磷布韦治疗方案用于慢性丙型肝炎病毒(HCV) 感染患者的安全性和有效性的批准上市后研究 |
|
Scientific title: |
A phase IV Study to Evaluate the Safety and Effectiveness of Sofosbuvir-containing Treatment Regimens in Patients with Chronic Hepatitis C Virus (HCV) Infection in a Chinese Real-World Setting |
|
研究课题代号(代码): Study subject ID: |
GS-CN-334-4624 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杜姝 |
研究负责人: |
Alan Liping Zhao (赵立平) |
|
Applicant: |
Shu Du |
Study leader: |
Alan Zhao |
|
申请注册联系人电话: Applicant telephone: |
+86 13426320297 |
研究负责人电话:
Study leader's |
+86 18618178535 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shu.du@gilead.com |
研究负责人电子邮件: Study leader's E-mail: |
alan.zhao@gilead.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区建国门外大街1号国贸大厦A座51层吉利德 |
研究负责人通讯地址: |
北京市朝阳区建国门外大街1号国贸大厦A座51层吉利德 |
|
Applicant address: |
51st Floor, China World Tower A, 1 Jianguomenwai Avenue, Beijing, China |
Study leader's address: |
51st Floor, China World Tower A, 1 Jianguomenwai Avenue, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
吉利德(上海)医药科技有限公司 |
||
|
Applicant's institution: |
Gilead Sciences Shanghai Parmaceutical Technology Co.,Ltd. |
||
|
研究负责人所在单位: |
吉利德(上海)医药科技有限公司 |
||
|
Affiliation of the Leader: |
Gilead Sciences Shanghai Parmaceutical Technology Co.,Ltd. |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
19081-1-01;19081-01-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京清华长庚医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics committee of Beijing Tsinghua Changgung Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2019-04-18 00:00:00 | ||
|
伦理委员会联系人: |
刘曼婷 |
||
|
Contact Name of the ethic committee: |
Manting Liu |
||
|
伦理委员会联系地址: |
北京市昌平区立汤路168号 |
||
|
Contact Address of the ethic committee: |
168 Litang Road, Changping District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10-56118567 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
IRB@btch.edu.cn |
|
研究实施负责(组长)单位: |
北京清华长庚医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Beijing Tsinghua Changgung Hospital |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市昌平区立汤路168号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
168 Litang Road, Changping District, Beijing, China |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
吉利德(上海)医药科技有限公司 |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Gilead Sciences Shanghai Pharmaceutical Technology.,Ltd |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
慢性丙型肝炎 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
HCV |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
此批准上市后研究将收集和评估有关含有索磷布韦的治疗方案在中国常规临床实践中治疗慢性HCV 感染患者的安全性和有效性的信息。 本研究的主要目标是: -描述在常规临床实践中使用含有索磷布韦方案治疗慢性 HCV 感染患者的不良事件发生率; 本研究的次要目标是: -描述停止治疗后约 12 周的持续病毒学应答率,其定义为停止治疗后约12 周时HCV RNA < LLOQ 患者的比例。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
This study will collect and assess data related to the safety and effectiveness of sofosbuvir-containing treatment regimens, per the approved prescribing information, in routine clinical practice. Primary objective: To determin the rates of adverse events (AEs) in patients with chronic HCV infection treated with sofosbuvir-containing regimens in routine clinical practice. Secondary objective: To determine the sustained virologic response (SVR) rates at approximately 12 weeks after cessation of treatment, defined as the proportion of patients with HCV RNA < lower limit of quantification (LLOQ) at approximately 12 weeks after cessation of treatment. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
1.按照中国国家药品监督管理局批准的当地处方信息有资格开始使用含有索磷布韦治疗方案的中国慢性丙型肝炎感染患者。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
Chinese patients with chronic hepatitis C infection, who are eligible to initiate sofosbuvircontaining regimens, according to the local prescribing information approved by CNDA. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1 同时参加 HCV 治疗的临床试验(不测试研究用药的试验除外); |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. Participating in clinical trial of HCV treatment in same time (except trials not testing investigational medicinal products); |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2018-10-23 00:00:00至 To 2022-04-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2019-05-28 00:00:00 至 To 2021-03-03 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非干预性研究不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Noninterventional study and N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ChiCTR (Chinese Clinical Trial Registry); http://www.chictr.org.cn/index.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ChiCTR (Chinese Clinical Trial Registry); http://www.chictr.org.cn/index.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
一为病例记录表,二为电子采集和管理系统(iMedidata Rave) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
One is CRF and the second is EDC (iMedidata Rave) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |